Wenbin Liu1, Dijiong Wu1, Tonglin Hu1, Baodong Ye1. 1. Department of Hematology, First Hospital Affiliated to Zhejiang Chinese Medical University Hangzhou, China.
Abstract
OBJECTIVE: The purpose of our study was to evaluate the efficacy and safety of rituximab in treatment of immune PR. METHODS: We retrospective analysis 7 paitents (5 aplastic anemia, 2 myelodysplastic syndrome) with immune PR who received at least 3 weekly infusions of rituximab (375 mg/m(2)). RESULTS: All enrolled patients acquired improvement of platelets transfusion more than 2 months (CCI ≥ 4.5 × 10(9)/L). We first found that there were 2 patterns of response to rituximab treatment in patients with immune PR, which the early but transient after the first rituximab administration and the late but continuous beginning to appear at 3 weeks from the start of treatment. CONCLUSION: Rituximab is a promising treatment in patients with immune PR and giving the opportunity and time for cure the disease.
OBJECTIVE: The purpose of our study was to evaluate the efficacy and safety of rituximab in treatment of immune PR. METHODS: We retrospective analysis 7 paitents (5 aplastic anemia, 2 myelodysplastic syndrome) with immune PR who received at least 3 weekly infusions of rituximab (375 mg/m(2)). RESULTS: All enrolled patients acquired improvement of platelets transfusion more than 2 months (CCI ≥ 4.5 × 10(9)/L). We first found that there were 2 patterns of response to rituximab treatment in patients with immune PR, which the early but transient after the first rituximab administration and the late but continuous beginning to appear at 3 weeks from the start of treatment. CONCLUSION:Rituximab is a promising treatment in patients with immune PR and giving the opportunity and time for cure the disease.